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Abstract:  
A series of N,N’-bis(arylmethyl)benzimidazolium salts with hydrophilic and lipophilic 
substituents have been synthesized, characterized, and tested against select non-small cell cancer 
cell lines. Substituent variations on the imidazole ring have shown that lipophilicity and 
hydrophilicity can influence the imidazolium salts’ anti-proliferative activity and aqueous 
solubility. 
Introduction 
Cancer is a major disease with more than one million people being diagnosed each year in 
the United States alone. Pharmaceuticals presently used can be toxic to the patient and, over 
time, can lead to an increased tolerance level of the patient’s cancer cells. Cancer is characterized 
by the abnormal cell growth and rapid cell division due to damaged DNA, and results in 
hundreds of thousands of deaths every year.  According to the American Cancer Society, 585,720 1
cancer related deaths are predicted in the United States alone during the year of 2014.  Presently, 2
research efforts are being devoted to drug formulation and alternative treatments for the growing 
cancer epidemic. The disadvantage of current cancer medications is the association with 
numerous side effects. For example, cisplatin, a commonly used chemotheraputic, has been 
known to affect auditory and digestive functions, cause skin damage, and induce kidney failure.  3
Current research is focused on finding alternatives to cisplatin with equivalent anti-proliferative 
activity and fewer side effects. This has led to the exploration of imidazolium salts. Synthetic 
modifications to these compounds are intended to maximize their anti-proliferative activity and 
their aqueous solubility, with the intention of minimizing additional health risks. , , ,  Research in 4 5 6 7
the Youngs group has been concentrated on developing N,N’-bis(naphthylmethtyl)imidazolium 
salts. One N,N’-bis(naphthylmethyl)imidazolium salt shown to have anti-proliferative activity is 
IC23 (Figure 1).  This salt has shown comparable activity to cisplatin. 8
 
Figure 1. Structure of IC23 (1). 
Initial studies began with the C4 and C5 positions of the imidazole ring and led to the 
synthesis and screening of salts 2 and 3 (Figure 2). Salts 1-3 showed anti-proliferative activity 
comparable to the control, cisplatin, and further proved that the salts activity was not hindered 
by the substituent variation in the C4 and C5 positions. However, salt 2, like IC23, was limited by 
its aqueous solubility, which led to the investigation of hydrophilic solubilizing groups on the 
benzimidazole ring.  
N1
C5 C4
N3
C2
ClCl
Br
!  
Figure 2. Structures of N,N’-bis(naphthylmethyl)imidazolium salt of 2 and 3. 
A series of N,N’-bis(naphthylmethyl)benzimidazolium salts with solubilizing groups 
substituted on the benzimidazole ring have been synthesized and screened. Recently, focus has 
been concentrated on changing the functionality at the C2 position of the benzimidazole ring to 
monitor the substituent’s effect on the anti-proliferative activity. Functional groups previously 
explored at the C2 position included acids, esters, and alkyl groups. Two additional 
functionalities of interest are alcohol and ether linkages at the C2 position. Alcohol and ether 
linkages warranted investigation because, theoretically, the oxygen atoms can offer sites of 
hydrogen bonding with water molecules, increasing its aqueous solubility.  
The alcohol functional groups provide hydrophilicity through hydrogen bonding. This 
additional hydrophilicity can help to increase the aqueous solubility of the benzimidazole. 
However, previously synthesized compounds have shown that substituting a short chained 
alcohol group directly onto the imidazole ring can adversely affect the anti-proliferative activity. 
The anti-proliferative activity of these salts, a series of N,N’-bis(arylmethyl)benzimidazolium 
salts with an extended alcohol functionality at the C2 position, were tested against a panel of non-
small cell lung cancers (NSCLCs) and reported. The propanol substituent is useful for 
determining if increasing the distance of the alcohol group from the benzimidazole ring would 
allow these benzimidazolium salts to retain the anti-proliferative activity and provide additional 
the aqueous solubility (Figure 3). 
!  
Figure 3. Structures of 2-(3-hydroxypropyl)-N,N’-bis(arylmethyl)benzimidazolium salts. 
Variation of the substituents at the N1 and N3 positions of the 2-(3-hydroxypropyl) series 
included quinolinylmethyl and (6-methoxynaphthyl)methyl substituents, along with the 
naphthylmethyl explored in this paper. The modification of the naphthalene portion with 
heteroatoms and additional substitution was theorized to aid in providing additional water 
solubility for this novel series of benzimidazolium salts. 
In addition to the alcohol moiety, the water solubility of N,N’-
bis(arylmethyl)benzimidazolium salts can also be modified by incorporating other solubilizing 
groups onto the benzimidazole, such as a polymeric ethylene glycol (PEG) chain. These PEG 
groups have previously been explored by researchers to increase the hydrophilic properties of 
molecules and to increase the overall solubility of molecules. These PEG chains were used in 
shells for encapsulating metal ions and as a potential delivery system for drugs. ,  In an attempt 9 10
to increase the aqueous solubility and maintain anti-proliferative activity of these 
benzimidazolium salts, two N,N’-bis(arylmethyl)benzimidazolium salts with a triethylene glycol 
(TEG) group, a derivative of the PEG family, at the C2 position were synthesized, characterized, 
and tested against a panel of NSCLC cell lines (Figure 4). These two salts with an extended ether 
functionality at the C2 position were theorized to have increased hydrophilic properties and 
solubility of benzimidazolium salts through neighboring hydrogen bonding interactions of the 
solvent. Variation of the substituents at the N1 and N3 positions included a quinolinylmethyl 
substituent, along with the naphthylmethyl explored in this paper. The comparison of 
bis(quinolinylmethyl) versus bis(naphthylmethyl) salts also provided insight for a novel system 
of benzimidazolium salts. 
!  
Figure 4. Structures of 2-((2-(2-methoxyethoxy)ethoxy)methyl)-N,N’-bis-
(arylmethyl)benzimidazolium salts. 
Results and Discussion 
The 2-(3-hydroxypropyl)-benzimidazole (4) and the 2-(3-hydroxypropyl)-N,N’-
bis(arylmethyl)-benzimidazolium salts (5-9) were synthesized according to the reaction in 
Scheme 1. Compound 4 was synthesized by a literature reaction  and the addition of the 11
substituents to N1 and N3 atoms followed procedures similar to those previously used by the 
group on other imidazole based compounds.8 Compound 4 was stirred with 1.1 equivalent of 
potassium hydroxide and one equivalent of the appropriate alkyl bromide or chloride in refluxing 
acetonitrile overnight to generate the mono-substituted intermediate, which was later stirred with 
a second equivalent of the appropriate alkyl halide to yield the corresponding salts 5-9.8 
  
!  
Scheme 1. Synthesis of 2-(3-hydroxypropyl)-N,N’-bis(arylmethyl)benzimidazolium salts, 5-9. 
Three symmetric compounds, 5, 8, and 9, featuring the propanol group at the C2 position 
were synthesized, each with different substituents at the N1 and N3 positions (Figures 5 and 
Figure 8). The bis(naphthylmethyl) salt 5 was synthesized and tested in order to draw a 
comparison to IC23, due to the previous salt’s high anti-proliferative activity. The 
quinolinylmethyl and (6-methoxynaphthyl)methyl substituents of 8 and 9, respectively, provided 
structural similarity to 5 and with the addition of heteroatom – nitrogen and oxygen – potentially 
provided sites for more hydrogen bonding interactions. Additionally, two asymmetric compounds 
6 and 7 were synthesized using both the naphthylmethyl and quinolinylmethyl substituents, 
featuring two variations in the accompanying anion (Figures 6 and Figure 7). The asymmetric 
nature of the compounds were used to test what effect two differing substituent groups at the N1 
and N3 positions had on the anti-proliferative activity and aqueous solubility of the salts. The 
variation in the anion of 6 and 7 was due to the different alkylating agent included at the second 
step when synthesizing the salts. 
Compounds 5-9 were analyzed via proton NMR spectroscopy. The compounds all had 
resonance indicative of the benzimidazole ring and the aromatic substituents of the nitrogen 
atoms at 8.50, 8.04-7.87, 7.79, 7.77-7.67, 7.63-7.55, 7.48, the resonance of the hydrogen of the 
alcohol group at 6.28, the resonance of the methylene groups off of the two substituents at 6.15, 
and the resonances of the hydrogen atoms bonded to the carbon atoms of the propyl chain at 
4.85, 3.53-3.47, and 1.86. 
Crystals of the salts, 5-8, suitable for single X-ray diffraction were obtained by slow 
evaporation. Data collected through X-ray crystallography helped determine the structures for 
5-8. The data compiled for compound 5, which was crystallized from methanol, showed that the 
naphthylmethyl substituents appeared to repel each other and the alcohol group (Figure 5). The 
structure of compound 8, crystallized from water and acetone, featured the two quinolinylmethyl 
substituents and appeared to adopt a different orientation (Figure 8). The substituents are directed 
straight forward off the benzimidazole ring and the alcohol functionality stretches up from the 
benzimidazole ring, appearing to form a 90 degree angle with the quinoline groups. This may be 
due to the salt maximizing hydrogen bonding interactions with surrounding water molecules by 
stretching the heteroatoms, the nitrogen atoms and the oxygen, away from each other. 
!  
Figure 5. Thermal ellipsoid plot of 5 with thermal ellipsoid plots at 50% probability level. 
The two asymmetric 2-(3-hydroxypropyl)-N,N’-bis(arylmethyl) benzimidazolium salts, 
compounds 6 and 7, showed similar results in their X-ray crystallography data. Compound 6 was 
crystallized in a combination of water, ethyl acetate, and acetone. Compound 7 was crystallized 
in a combination of water, methanol, and acetone. Both 6 and 7 had the alcohol orient toward the 
quinoline-portion of the substituent (Figure 6 and Figure 7). This may imply hydrogen bonding 
interactions between the nitrogen atom and the alcohol group, which may cause the alcohol and 
the quinoline substituent to hydrogen bond in the same area. However, reviewing the thermal 
ellipsoid plots of compound 8, it was shown that the alcohol seemed to repel the quinoline 
groups. The configuration of compounds 6 and 7 may be because the alcohol was interacting 
with the hydrogen of the nitrogen atom of the quinolinylmethyl substituent in a way it was 
unable to do in compound 8. This configuration was also an excellent example of potential 
intramolecular hydrogen bonding, a phenomenon which is further illustrated in the 2-((2-(2-
methoxyethoxy)ethoxy)methyl)-N,N’-bis-substituted benzimidazolium salts. 
!  
Figure 6. Thermal ellipsoid plot of 6 with thermal ellipsoid plots at 50% probability level. 
Hydrogen atoms omitted for clarity. 
!  
Figure 7. Thermal ellipsoid plot of 7 with thermal ellipsoid plots at 50% probability level. 
Hydrogen atoms omitted for clarity. 
!  
Figure 8. Thermal ellipsoid plot of 8 with thermal ellipsoid plots at 50% probability level. 
Hydrogen atoms omitted for clarity. 
A series of 2-((2-(2-methoxyethoxy)ethoxy)methyl)-N,N’-bis-substituted benzimidazolium 
salts were synthesized using the method found in Scheme 2. Equivalent portions of 5,6-
Dimethyl-1,2-benzenediamine and 2-(2-[2-methoxy]ethoxy)ethoxy-acetic acid were refluxed in 
4M aqueous hydrochloric acid. Following the synthesis and characterization of 10, the reaction 
was optimized to minimize possible contamination or side products. The two reagents, 5,6-
dimethyl-1,2-benzenediamine and 2-(2-[2-methoxy]ethoxy)ethoxy-acetic acid, were heated at 
140 °C in a neat reaction. Furthermore, the purity of the 2-(2-[2-methoxy]ethoxy)ethoxy-acetic 
acid was increased from a synthesis grade (≥ 90%) to a technical grade (≥ 95%). 
The benzimidazolium salts 2-((2-(2-methoxyethoxy)ethoxy)methyl)-5,6-dimethyl-1,3-
bis(naphthalen-2-ylmethyl)-benzimidazolium bromide (11) and 2-((2-(2-
methoxyethoxy)ethoxy)methyl) -5,6-dimethyl-1,3- bis(quinolin-2-ylmethyl)-benzimidazolium 
chloride (12) were synthesized from 10, according to an established procedure in our laboratory 
for similar lipophilic systems (Scheme 2). Compound 10 was stirred with 1.2 equivalent of 
potassium hydroxide and one equivalent of the appropriate alkyl bromide or chloride in refluxing 
acetonitrile overnight to generate the mono-substituted intermediate, which was later stirred with 
a second equivalent of the appropriate alkyl halide to yield the corresponding salts 11-12. These 
benzimidazolium salts featured the inclusion of methyl groups at the C5 and C6 positions of the 
benzimidazole ring that gave the molecules more lipophilicity. Like the 2-(3-hydroxypropyl)-
N,N’-bis(arylmethyl)benzimidazolium salts 5-9, 11 and 12 were fully characterized. Crystals of 
12, suitable for single X-ray diffraction was obtained by slow evaporation of a concentrated 
solution of isopropanol and minimal chloroform (Figure 9). 
!  
Scheme 2. Synthesis of 2-((2-(2-methoxyethoxy)ethoxy)methyl)-N,N’-
bis(arylmethyl)benzimidazolium salts, 11-12. 
Interestingly, the (2-(2-(2-methoxyethoxy)ethoxy)methyl)-portion was quite complex in 
the NMR spectra when progressing from 10 to both 11 and 12. Compound 10 appeared as a 
yellow oil, and showed slight impurities in the material following analysis in the 300 Hz ¹H 
NMR. These impurities were removed by column chromatography using a (50:50) ethyl acetate 
and hexanes mixture as the eluent. The fractions were evaluated using TLC plates and NMR 
spectroscopy, with the fourth fraction clearly containing the desired product (Figure 9). In the 
final and nearly-purified form, the product was a yellow oil. There was one remaining impurity 
in the NMR data at 4.04 ppm. Comparison of the NMR spectra with NMR spectra of the two 
starting materials showed that the resonance of 4.04 ppm was the result of unreacted 2-(2-[2-
methoxy]ethoxy)ethoxy-acetic acid. The remaining acid was removed using a sodium 
bicarbonate wash on the product (Figure 10). The post-wash NMR spectroscopy also shows a 
slight differentiation between the hydrogens at the C4 and C7 positions (7.20 ppm and 7.32 ppm) 
of the benzimidazole and the hydrogens of the methyl groups at the C5 and C6 positions (2.26 
ppm and 2.28 ppm). This separation of peaks implies there may be hydrogen bonding 
interactions between the hydrogen of the nitrogen atom in the benzimidazole and one or more of 
the oxygen atoms in the triethylene glycol chain, resulting in an asymmetric molecule. This data 
supports the original hypothesis that the triethylene glycol chain is capable of hydrogen bonding 
interactions and may increase the overall hydrophilicity of the molecule. 
!  
Figure 9. 300 Hz ¹H NMR data for fraction 4. Spectrum displayed resonances of 5,6-dimethyl-2-
methoxy-triethyleneglycol-benzimidazole and column eluent, (50:50) ethyl acetate and hexanes. 
    
Figure 10. 300 Hz ¹H NMR data of 5,6-dimethyl-2-methoxy-triethyleneglycol-benzimidazole 
pre-wash, 2-(2-[2-methoxy]ethoxy)ethoxy-acetic acid, and 5,6-dimethyl-2-methoxy-
triethyleneglycol-benzimidazole post-wash. Resonances per salt 11 depicted in red (pre-wash) 
and blue (post-wash). Resonances per acid starting material depicted in green. 
The N,N’-bisnapthyl-5,6-dimethyl-2-methoxy-TEG-benzimidazolium salt, compound 11, 
was the first to be synthesized. The initial stirring of the 5,6-dimethyl-2-methoxy-
triethyleneglycol-benzimidazole with the base for 30 minutes is meant to deprotonate the 
nitrogen atom, allowing the naphthalene substituent to bind to the nitrogen. 2-(Bromomethyl)-
naphthalene was added one equivalent at a time so that the potassium bromide salt formed in the 
first step of the reaction may be removed at the halfway point via a hot vacuum filtration. 
*
*
DMSO
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However, the N,N’-bisnapthyl-5,6-dimethyl-2-methoxy-TEG-benzimidazolium salt still appeared 
as a yellow oil, and ¹H NMR showed impurities in the spectrum, so it was purified through 
column chromatography. 
Following the TLC analysis, which showed salt 11 was more polar than the starting 
benzimidazole 5,6-dimethyl-2-methoxy-TEG-benzimidazole 10, the eluent used to purify 11 was 
a (5:95) methanol and chloroform mixture. The solvent from the final fraction of the column was 
removed under reduced pressure to produce a white powder, and the powder was analyzed on the 
400 Hz NMR (Figure 11). The NMR spectroscopy data clearly shows resonance at 6.06, which is 
indicative of the methylene hydrogens on the naphthalene substituents, another resonance at 
5.35, which is indicative of the methylene at the 2 position of the benzimidazole, and splitting 
ranging from 3.72 to 3.09, which is representative of the hydrogens in the triethylene glycol 
chain. 
!  
Figure 11. 400 Hz ¹H NMR data; post-column N,N’-bisnapthyl-5,6-dimethyl-2-methoxy-TEG-
benzimidazolium salt, 11. (Artifact at approximately 6.00 ppm) 
!  
Figure 12. Aliphatic region of the 400 Hz ¹H NMR data shown in Figure 11; post-column N,N’-
bisnapthyl-5,6-dimethyl-2-methoxy-TEG-benzimidazolium salt, 12. 
Compound 12 was synthesized incorporating quinolinylmethyl substituents at the N1 and 
N3 positions, using the same procedure of compound 11. Similar to 11, compound 12 appeared as 
a yellow oil following the final hot acetonitrile wash. 1H NMR data showed that the desired 
product was present in the oil, and the product was purified and isolated by column 
chromatography using a (5:95) methanol and chloroform mixture as the eluent. The product still 
appeared as a yellow oil following the column filtration, however it was determined that an 
isopropanol wash could precipitate a white powder out of the solution.  
In Vitro Anti-Proliferative Activity 
Following synthesis and characterization, the activity of these compounds were tested 
against NSCLC lines, including NCI-H460, NCI-H1975, HCC827 and NCI-A549 to determine 
their anti-proliferative activity via MTT assay analysis (Table 1). The activity was analyzed by 
the concentration required to inhibit function of half the cells in a given cell colony, known as 
IC50 values. Cisplatin, a commonly used chemotherapeutic, was used as a control for the assays. 
The target of the assays was to screen for synthesized compounds that had IC50 values 
comparable to or lower than those of cisplatin against the four NSCLC lines. 
The N,N’-bis(arylmethyl)-2-(3-hydroxypropyl) benzimidazolium salts, 5-9, had a wide 
range of anti-proliferative activity. Compound 5, the least hydrophilic of the salts, had IC50 
values comparable to both the cisplatin control and the compound IC23 (1), ranging from 6-10 
µM, which is indicative of moderate activity. Furthermore, 5 had IC50 values lower than cisplatin 
against the cell line NCI-H1975, with a value of 4 µM (which indicates high activity) compared 
to cisplatin’s value of 11 µM for NCI-H1975 (which indicates moderate to low activity). 
Compound 8 had IC50 values ranging from 11-25 µM, indicative of moderate to poor activity, on 
three of the four cell lines, and fell far short of the high activity values of cisplatin. The poor 
activity values of 8 may be due to the nitrogen atoms found in the quinolinylmethyl substituents, 
which were used to increase the molecules hydrophilicity. This theory is further supported by the 
fact that compound 9, which featured the two (6-methoxynaphthyl)methyl substituents, had IC50 
values of 7 µM,4 µM, and 8 µM for NCI-H460, NCI-H1975, and HCC827, respectively. 
Compound 9 has heteroatoms in the (6-methoxynaphthyl)methyl substituents to increase 
hydrophilicity, but uses oxygen atoms rather than nitrogen atoms. Since the IC50 values of 9 are 
lower than those of 8, it could be hypothesized that the nitrogen atoms are the cause of the 
decrease in activity. The asymmetric salt, compound 7, had IC50 values for cell lines NCI-H460 
and HCI-H1975 comparable to cisplatin and 5, however the IC50 values for lines HCC827 and 
NCI-A549 were still higher than those for compound 5.  
Compound 11 was shown to have excellent activity, with IC50 values for all cell lines 
ranging from less than 1 µM to 2 µM, but was also found to have very little aqueous solubility. 
Even with the addition of multiple heteroatoms at the C2 position, there was not enough 
hydrophilicity for 11 to easily solubilize in water. However, the low IC50 values are encouraging 
in that they are both lower than the IC50 values of cisplatin and show that other N,N’-
bis(arylmethyl)-5,6-dimethyl-2-methoxy-TEG-benzimidazolium salts with more heteroatoms 
substituted into the molecules may have the combination of aqueous solubility and anti-
proliferative activity that has been the goal of this research. 
Table 1. Synthesized N,N’-bis(arylmethyl)benzimidazolium salts with their relevant IC50 values. 
Conclusion 
 The investigation by the Youngs research group into imidazole based compounds with 
anti-proliferative activity has yielded results that may impact the development of new treatments 
for NSCLC and possibly other cancer lines. The key to these compounds was finding a balance 
between the anti-proliferative activity and the aqueous solubility. Work with the 2-(3-
hydroxypropyl)-N,N’-bis(arylmethyl) benzimidazolium salts, 5-9, showed the relationship 
between activity and aqueous solubility clearly in the MTT assays. 
 Compound 5 had IC50 values comparable to those of cisplatin, whereas compound 8, 
which featured quinolinylmethyl substituents containing nitrogen atoms, proved to have much 
Compound
IC-50 (µM)
NCI-H460 NCI-H1975 HCC827 NCI-A549
Cisplatin 3 11 5 7
1 5 6 8 9
2 4 4 5 5
3 5 6 9 10
5 4 4 6 10 
6 13 3 7 17
7 4 3 11 12
8 11 7 17 25
9 7 4 8 13
11 < 1 < 1 2 2
higher values, though better aqueous solubility. The exception was compound 9, which featured 
(6-methoxynapthyl)methyl substituents. Compound 9 proved to have lower IC50 values than 
compound 8, but also maintained higher levels of aqueous solubility. This result may imply some 
relationship between the addition specifically of nitrogen atoms and a loss of anti proliferative 
activity. 
 The N,N’-bis(arylmethyl)-5,6-dimethyl-2-methoxy-TEG benzimidazolium salts, 11 and 
12, proved to be complex to synthesize, however tracking the synthesis through NMR 
spectroscopy was able to show not only the purification of the products, but some weak 
hydrogen bonding interactions. Compound 11 showed high anti proliferative activity in the MTT 
assay screenings, though it had poor aqueous solubility. However, due to the low IC50 values of 
11, it may be inferred that similar salts with more hydrophilic groups substituted at the N1 and N3 
positions, such as those found in quinolinylmethyl and (6-methoxynapthyl)methyl, may provide 
the balance of aqueous solubility and anti-proliferative activity needed to advance to the next 
stage of medical testing.  
Experimental 
General Considerations 
All reactions were carried out under aerobic conditions unless otherwise specified. All 
reagents and solvents were purchased from commercial sources and used without further 
purification. 2-((2-(2-Methoxyethoxy)ethoxy)-acetic acid (≥95%) was purchased from Merck. 
4,5-Dimethyl-o-phenylene diamine mono-hydrate (98%) was purchased from Alfa Aesar. 2-
(Bromomethyl)naphthalene and 2-(chloromethyl)quinolone were purchased from Waterstone 
Technologies. 2-(Chloromethyl)-6-methoxynaphthalene, which was synthesized according to the 
literature.12 3-(Benzimidazol-2-yl)propan-1-ol (4) was synthesized according to literature 
procedure.  Column chromatography utilized silica gel (60 Å, ICN Medicals) embedded with 12
fluorescent indicator green 254 nm (Fluka Analytical). Melting points were obtained on a 
MelTemp apparatus. 1H and 13C nuclear magnetic resonance (NMR) spectra were collected on a 
Varian 500 MHz instrument referenced to DMSO-d6 (Cambridge Isotope Laboratories, (δ = 2.50 
ppm, 39.51 ppm). Infrared spectroscopy (IR) was performed with a Thermo Scientific ATR -IR 
Nicolet iS5 FT-IR spectrometer equipped with an iD5 ATR attachment. Electrospray ionization 
mass spectrometry (ESI-MS) and (ESI-HRMS) were performed by the University of Akron mass 
spectrometry laboratory (Akron, OH). Elemental analysis was performed by the microanalysis 
laboratory at Atlantic Microlabs, Inc. (Norcross, GA) or by the University of Akron Department 
of Geology (Akron, OH).  
Crystal structures were obtained by Patrick O. Wagers. Crystals of the compounds were 
coated in paratone oil, mounted on a CryoLoop and placed on a goniometer under a stream of 
nitrogen. Crystal structure data sets were collected on either a Bruker APEX CCD diffractometer 
with graphite-monochromated Mo Kα radiation (λ = 0.71073 Å) or a Bruker Kappa APEX II 
Duo CCD system equipped with a Mo ImuS source and a Cu ImuS micro-focus source equipped 
with QUAZAR optics (λ = 1.54178 Å). The unit cells were determined by using reflections from 
three different orientations. Data integration and reduction were performed in the Apex2 suite 
using SAINT.  An empirical absorption correction and other corrections were applied to the data 13
using multi-scan SADABS.  Structure refinement and solution was accomplished using the 14
Bruker SHELXTL software package.  The structures were determined by full-matrix least-15
squares refinement of F2 and the selection of the appropriate atoms from the generated 
difference map. Hydrogen atom positions were calculated and Uiso(H) values were fixed 
according to a riding model. 
The human non-small cell lung cancer cell lines NCI-H1975, NCI-H460, NCI-A549 and 
HCC827 were donated by Dr. Lindner from the Cleveland Clinic. The human non-small cell lung 
cancer cell line NCI-H460 was purchased from ATCC (Manassas, VA, USA). All cell lines were 
grown in RPMI 1640 media supplemented with 10% fetal bovine serum. All cell lines were 
grown under physiological conditions, specifically at 37 °C with 5% CO2 and passed every 2-3 
days. 
Cells were grown to confluency and plated in 96-well plates at 5,000-7,000 cells per well. 
Cells were incubated for 24 h prior to adding the compounds. All compounds were dissolved in a 
1% DMSO solution and diluted in fresh media to the desired concentrations of 1, 4, 16, and 32 
mM. Compounds were added in sextuplet and cells were incubated for 72 h at which time the 
optional MTT assay protocol was followed. MTT reagent (10 mL) was added to each well and 
cells were incubated for 3-4 h. Media was removed by vacuum and DMSO (100 mL) was added 
to each well. Plates were incubated for 15 min at 37 °C. The optical density was read at 540 nm 
on a BioTek Epoch plate reader. 
3-(1-(naphthalen-2-ylmethyl)-benzimidazol-2-yl)propan-1-ol (4a). 3-(Benzimidazol-2-
yl)propan-1-ol (4) (1.99 g, 11.3 mmol) was dissolved in acetonitrile (57 mL) potassium 
hydroxide (0.718 g, 12.8 mmol) was added, and the mixture was refluxed for 30 min. 2-
(Bromomethyl)naphthalene (2.50 g, 11.3 mmol) was added and the mixture was refluxed for 30 
min. The reaction mixture was filtered hot to remove a white solid, presumed to be potassium 
bromide. The resulting filtrate was slowly evaporated to yield crystalline material. The crystals 
were washed in ether (20 mL), collected via vacuum filtration and air dried to yield a white 
powder 4a (1.85 g, 51%). Mp: 126 – 127 °C. Anal. Calcd for C21H20N2O: C, 79.72; H, 6.37; N, 
5.06%. Found: C, 79.79; H, 6.39; N, 8.85%. 1H NMR (500 MHz, DMSO- d6) 7.89-7.87 (m, 2H), 
7.83-7.80 (dd, 1H, J = 6.0, 3.4 Hz), 7.61-7.57 (m, 2H), 7.51-7.45 (m, 3H), 7.27 (dd, 1H, J = 8.5, 
1.8 Hz), 7.18-7.10 (m, 2H), 5.65 (s, 2H), 4.57 (s, 1H), 3.50 (q, 2H, J = 6.1 Hz), 2.94 (t, 2H, J = 
7.6 Hz), 1.94 (dt, 2H, J = 6.8 Hz). 13C {1H} NMR (125 MHz, DMSO-d6) 155.3, 142.3, 135.3, 
134.6, 132.8, 132.2, 128.4, 127.6, 126.4, 124.8, 124.6, 121.6, 121.3, 118.4, 110.1, 60.0, 46.2, 
30.2, 23.4. 
 
2-(3-hydroxypropyl)-1,3-bis(naphthalen-2-ylmethyl)-benzimidazolium bromide (5). 3-
(Benzimidazol-2-yl)propan-1-ol (4) (1.50 g, 8.51 mmol) was dissolved in acetonitrile (40 mL) 
potassium hydroxide (0.90 g, 16.0 mmol) was added, and the mixture was refluxed for 30 min. 
2-(Bromomethyl)naphthalene (1.90 g, 8.59 mmol) was added and the mixture was refluxed 
overnight. The reaction mixture was filtered hot to remove a white solid, presumed to be 
potassium bromide. 2-(bromomethyl)naphthalene (1.90 g, 8.59 mmol) was added to the filtrate, 
which was refluxed overnight.  The resulting precipitate was collected via vacuum filtration of 
the hot mixture. The solid in the funnel as washed with diethyl ether (10 mL) and air dried to 
yield a white powder 5 (2.20 g, 48 %). Mp: 229 – 231 °C. Anal. Calcd for C32H29BrN2O: C, 
71.02; H, 5.61; N, 5.08%. Found: C, 71.51; H, 5.44; N, 5.21%. 1H NMR (500 MHz, DMSO- d6) 
7.98 (d, 2H, J = 8.6 Hz), 7.94 (, 2H), 7.91-7.86 (m, 6H), 7.59-7.53 (m, 6H), 7.49 (dd, 2H, J = 8.4, 
1.6 Hz), 6.09 (s, 4H), 4.79 (bs, 1H), 3.54 (t, 2H), 3.49 (t, 2H, J = 5.6 Hz), 1.76 (dt 2H,). 13C {1H} 
NMR (125 MHz, DMSO-d6) 155.3, 132.7, 132.5, 131.8, 131.4, 128.7, 127.7, 127.6, 126.7, 
126.51, 126.45, 125.7, 124.7, 113.6, 59.2, 48.7, 29.7, 21.0. MS (ESI+) calcd for C32H29N2O+ [M-
Br]+: m/z = 457.2, found m/z = 457.1. 
Crystal data for 2-(3-hydroxypropyl)-1,3-bis(naphthalen-2-ylmethyl)-benzimidazolium bromide 
(5):C32H29Br1N2O1, M = 537.48, triclinic, a = 10.3959(6) Å, b = 10.4438(6) Å, c = 12.8557(7) Å, 
α = 67.842(2)°, β = 76.321(2)°, γ = 79.887(2)°,V = 1250.23(12) Å3, T = 100(2) K, space group 
P-1, Z = 2, 27063 reflections measured, 5022 independent reflections (Rint = 0.0277).The final R1 
values were 0.0221 (I > 2σ(I)). The final wR(F2) values were 0.0552 (I > 2σ(I)). The final R1 
values were 0.0237 (all data). The final wR(F2) values were 0.0561 (all data).  
2-(3-hydroxypropyl)-1-(naphthalen-2-ylmethyl)-3-(quinolin-2-ylmethyl)-benzimidazolium 
chloride salt (6). 3-(1-(naphthalen-2-ylmethyl)-benzimidazol-2-yl)propan-1-ol (4a) (0.20 g, 0.63 
mmol) and 2-(Chloromethyl)quinoline (0.29 g, 1.63 mmol) were dissolved in a refluxing mixture 
of acetonitrile and methanol (4:1, v/v, 5 mL), and the mixture was refluxed overnight. The 
resulting precipitate was collected via vacuum filtration of the hot mixture. The solid in the 
funnel as washed with diethyl ether (10 mL) and air dried to yield a crème powder 5 (0.18 g, 
58%). Mp: 250 – 252 °C. Anal. Calcd for C31H28ClN3O: C, 75.37; H, 5.71; N, 8.51%. Found: C, 
74.55; H, 5.81; N, 8.34%. 1H NMR (300 MHz, DMSO- d6) 8.50 (d, 1H, J = 8.5 Hz), 8.04-7.87 
(m, 7H), 7.79 (d, 1H, J = 8.5 Hz), 7.77-7.67 (m, 1H), 7.63-7.55 (m, 6H), 7.48 (d, 1H, J = 8.5 
Hz), 6.28 (s, 2H), 6.15 (s, 2H), 4.85 (bt, 1H, J = 4.8 Hz), 3.53-3.47 (m, 4H), 1.86 (dt, 2H). 13C 
{1H} NMR (125 MHz, DMSO-d6) 156.0, 153.6, 146.6, 137.5, 132.7, 132.5, 132.0, 131.6, 130.1, 
128.8, 128.2, 128.0, 127.7, 127.2, 126.9, 126.8, 126.59, 126.42, 126.39, 125.7, 124.5, 120.0, 
113.4, 113.4, 59.2, 49.5, 48.4, 29.8, 21.0. MS (ESI+) calcd for C31H28N3O+ [M-Cl]+: m/z = 458.2, 
found m/z = 458.0. 
Crystal data for 2-(3-hydroxypropyl)-1-(naphthalen-2-ylmethyl)-3-(quinolin-2-ylmethyl)-
benzimidazolium chloride (6): C31H28Cl1N3O1, M = 494.04, triclinic, a = 10.2508(5) Å, b = 
10.5009(6) Å, c = 12.5681(7) Å, α = 110.590(3)°, β = 96.855(2)°, γ = 102.225(2)°,V = 
1209.63(11) Å3, T = 100(2) K, space group P-1, Z = 2, 30199 reflections measured, 4908 
independent reflections (Rint = 0.0319).The final R1 values were 0.0376 (I > 2σ(I)). The final 
wR(F2) values were 0.0955 (I > 2σ(I)). The final R1 values were 0.0430 (all data). The final 
wR(F2) values were 0.0994 (all data). 
2-(3-hydroxypropyl)-1-(naphthalen-2-ylmethyl)-3-(quinolin-2-ylmethyl)-benzimidazolium 
bromide salt (7). 3-(Benzimidazol-2-yl)propan-1-ol (4) (0.40 g, 2.27 mmol) was dissolved in 
acetonitrile (11 mL) potassium hydroxide (0.15 g, 2.67 mmol) was added, and the mixture was 
refluxed for 30 min. 2-(Chloromethyl)quinoline (0.40 g, 2.26 mmol) was added and the mixture 
was refluxed overnight. The reaction mixture was filtered hot to remove a white solid, presumed 
to be potassium bromide. 2-(Bromomethyl)naphthalene (0.50 g, 2.26 mmol) was added to the 
filtrate, which was refluxed overnight.  The resulting precipitate was collected via vacuum 
filtration of the hot mixture. The solid in the funnel as washed with diethyl ether (5 mL) and air 
dried to remove any remaining 2-(bromomethyl)naphthalene. The solid was triturated in a hot 
mixture of acetone and dichloromethane (1:1 v/v, 6 mL) and gravity filtered to yield a white 
powder 7 (0.57 g, 46%). Mp: 246 – 250 °C. Anal. Calcd for C31H28BrN3O: C, 69.15; H, 5.24; N, 
7.80%. Found: C, 69.15; H, 5.15; N, 7.72%. 1H NMR (500 MHz, DMSO- d6) 8.51 (d, 1H, J = 
8.3 Hz), 8.04-7.81 (m, 7H), 7.81-7.48 (d, 1H, J = 8.3 Hz), 6.31 (s, 2H), 6.18 (s, 2H), 4.75 (bt, 
1H), 3.55-3.47 (m, 4H), 1.89 (dt, 2H). 13C {1H} NMR (125 MHz, DMSO-d6) 156.0, 153.6, 
146.6, 137.5, 132.7, 132.5, 132.0, 131.6, 131.1, 130.1, 128.8, 128.0, 127.7, 127.2, 126.9, 126.8, 
126.6, 126.42, 126.39, 125.7, 124.5, 120.0, 113.5, 113.4, 59.2, 49.5, 48.4, 29.8.  
Crystal data for 2-(3-hydroxypropyl)-1-(naphthalen-2-ylmethyl)-3-(quinolin-2-ylmethyl)-
benzimidazolium bromide (7): C31H28Br1N3O1, M = 538.47, triclinic, a = 10.4596(3) Å, b = 
10.4601(3) Å, c = 12.7946(4) Å, α = 113.0640(10)°, β = 97.215(2)°, γ = 99.6430(10)°,V = 
1241.21(6) Å3, T = 100(2) K, space group P-1, Z = 2, 29636 reflections measured, 5003 
independent reflections (Rint = 0.0271).The final R1 values were 0.0295 (I > 2σ(I)). The final 
wR(F2) values were 0.0741 (I > 2σ(I)). The final R1 values were 0.0310 (all data). The final 
wR(F2) values were 0.0750 (all data). 
2-(3-hydroxypropyl)-1,3-bis(quinolin-2-ylmethyl)-benzimidazolium chloride salt (8). 3-
(benzimidazol-2-yl)propan-1-ol (4) (0.39 g, 2.21 mmol) was dissolved in acetonitrile (5 mL) 
sodium carbonate (0.24 g, 2.26 mmol) was added, and the mixture was refluxed for 30 min. 2-
(Chloromethyl)quinoline (0.60 g, 3.38 mmol) was added and the mixture was refluxed overnight. 
The reaction mixture was filtered hot to remove a white solid, presumed to be potassium 
bromide. 2-(Chloromethyl)quinoline (0.60 g, 3.38 mmol) was added to the filtrate, which was 
refluxed overnight.  The resulting precipitate was collected via vacuum filtration of the hot 
mixture. The solid in the funnel as washed with diethyl ether (5 mL) and air dried yield a white 
powder 8 (0.81 g, 72%). Mp: 256 – 260 °C. HRMS (ESI+) calcd for C30H27N4O+ [M-Cl]+: m/z = 
459.2185, found m/z = 459.2193 1H NMR (500 MHz, DMSO- d6) 8.51 (d, 2H, J = 8.3 Hz), 8.02 
(d, 2H, J = 8.1 Hz), 7.98 (m, 2H), 7.79 (d, 2H, J = 8.6 Hz), 7.72-7.67 (m, 3H), 7.62-7.59 (ddd, 
2H, J = 8.1, 6.1, 2.0 Hz), 7.54 (m, 2H), 6.35 (s, 4H), 4.95 (t, 1H, J = 5.1 Hz), 3.58 (t, 2H, J = 7.7 
Hz), 3.46 (q, 2H, J = 5.4 Hz), 1.91 (tt, 2H). 13C {1H} NMR (125 MHz, DMSO-d6) 156.5, 153.9, 
146.7, 137.5, 131.4, 130.1, 128.4, 128.0, 127.2, 126.9, 126.3, 119.9, 113.4, 59.2, 49.7, 29.8, 21.0.  
Crystal data for 2-(3-hydroxypropyl)-1,3-bis(quinolin-2-ylmethyl)-benzimidazolium chloride 
(8):C30H27Cl1N4O1•H2O1, M = 513.02, monoclinic, a = 13.0575(11) Å, b = 19.4079(13) Å, c = 
10.2667(8) Å, α = 90°, β = 90.609(3)°, γ = 90°,V = 2601.6(3) Å3, T = 100(2) K, space group 
P2(1)/c, Z = 4, 41453 reflections measured, 5281 independent reflections (Rint = 0.0376).The 
final R1 values were 0.0336 (I > 2σ(I)). The final wR(F2) values were 0.0814 (I > 2σ(I)). The 
final R1 values were 0.0421 (all data). The final wR(F2) values were 0.0866 (all data). 
2-(3-hydroxypropyl)-1,3-bis((6-methoxynaphthalen-2-yl)methyl)-benzimidazolium chloride 
salt (9). 3-(Benzimidazol-2-yl)propan-1-ol (4) (0.30 g, 1.70 mmol) was dissolved in acetonitrile 
(2 mL), potassium hydroxide (0.13 g, 2.32 mmol) was added, and the mixture was refluxed for 
30 min. 2-(Chloromethyl)-6-methoxynaphthalene (0.35 g, 1.69 mmol) was added and the 
mixture was refluxed overnight. The reaction mixture was filtered hot to remove a white solid, 
presumed to be potassium bromide. 2-(Chloromethyl)-6-methoxynaphthalene (0.35 g, 1.69 
mmol) was added to the filtrate, which was refluxed overnight.  The resulting precipitate was 
collected via vacuum filtration of the hot mixture. The solid in the funnel as washed with diethyl 
ether (5 mL) and air dried to yield a white powder 9 (0.40 g, 48 %). Mp: 217 – 219 °C. HRMS 
(ESI+) calcd for C34H33N2O3+ [M-Cl]+: m/z = 517.2491, found m/z = 517.2474. 1H NMR (125 
MHz, DMSO- d6) 7.91 (m, 2H), 7.87-7.83 (m, 4H), 7.79 (d, 2H, J = 9 Hz), 7.57 (dd, 2H, J = 3.2, 
1.2 Hz), 7.43 (d, 2H, J = 8.6 Hz), 7.34 (m, 2H), 7.19 (d, 2H, J = 8.8 Hz), 6.02 (s, 4H), 4.93 (t, 
1H), 3.86 (s, 6H), 3.53 (t, 2H, J = 7.3), 3.47 (dt, 2H), 1.73 (dt, 2H). 13C {1H} NMR (125 MHz, 
DMSO-d6) 157.7, 155.1, 133.9, 131.4, 129.34, 129.30, 128.1, 127.6, 126.2, 125.9, 125.3, 119.3, 
113.7, 105.9, 59.2, 55.2, 48.6, 29.7, 21.0.  
2-((2-(2-methoxyethoxy)ethoxy)methyl) -5,6-dimethyl-benzimidazole (10). 4,5-
Dimethylbenzene-1,2-diamine (0.50 g, 3.67 mmol) was dissolved in 2-[2-(2-
Methoxyethoxy)ethoxy]acetic acid (0.68 mL, 4.41 mmol, d = 1.161 g/mL) and was refluxed 
overnight. The solution was extracted in dichloromethane (2x32 mL). The organic layers were 
combined, dried with magnesium sulfate and the volatiles were removed under reduced pressure 
to a brown, viscous oil. The oil was purified using a mobile phase of ethyl acetate/hexanes (1:1) 
to yield a clear orange liquid. The orange oil was dissolved in dichloromethane (5 mL) and 
stirred for 1 hr with sodium bicarbonate. Deionized water (10 mL) was added to the residue and 
the organic layer was extracted with dichloromethane (3x10 mL). The organic layers were 
combined, dried with magnesium sulfate, and the volatiles were removed under reduced pressure 
to yield a viscous, orange oil 10 (0.4605 g, 45%). HRMS (ESI+) calcd for C15H23N2O3+ [M+H]+ 
of m/z = 279.1709, found [M+H]+ of m/z = 279.1713. 1H NMR (300 MHz, DMSO-d6) δ 12.17 
(s, 1H), 7.33 (s, 1H), 7.21 (s, 1H), 4.63 (s, 2H), 3.64-3.61 (m, 2H), 3.58-3.54 (m, 2H), 3.53-3.49 
(m, 2H), 3.44-3.40 (m, 2H), 3.23 (s, 3H), 2.29 (s, 3H), 2.28 (s, 3H). 13C{1H} NMR (125 MHz, 
DMSO-d6) δ 150.4, 129.9, 113.8, 71.27, 69.6, 66.2, 58.0, 30.5, 19.8. 
2-((2-(2-methoxyethoxy)ethoxy)methyl) -5,6-dimethyl-1,3-bis(naphthalen-2-ylmethyl)-
benzimidazolium bromide (11). Compound 10 (1.00 g, 3.59 mmol) was dissolved in 
acetonitrile (10 mL) with potassium hydroxide (0.24 g, 4.31 mmol) and was refluxed for 30 min. 
2-(Bromomethyl)naphthalene (0.79 g, 3.59 mmol) was added and the mixture was refluxed 
overnight, during which a precipitate was formed. The reaction mixture was filtered hot to 
remove a white precipitate, presumed to be potassium bromide. The filtrate was stirred with 2-
(bromomethyl)naphthalene (0.79 g, 3.59 mmol) and refluxed overnight. The volatiles were 
removed under reduced pressure and the residue was washed in a mixture of diethyl ether and 
acetone (4:1 v/v, 265 mL). The initial precipitate was isolated via a room temperature vacuum 
filtration. The volatiles of the filtrate were removed under reduced pressure and purified by 
column chromatography using a mobile phase of methanol/chloroform (5:95) to yield a clear 
residue. The residue was washed diethyl ether (20 mL) at room temperature to afford a cream 
solid 11. (0.48 g, 21%). Mp: 163-166 °C. Anal. Calcd for C37H29BrN2O3: C, 69.48; H, 6.15; Br, 
12.49; N, 4.38. Found: C, 69.28; H, 6.12; N, 4.34%. 1H NMR (400 MHz, DMSO-d6) δ 7.97 (s, 
2H), 7.95-7.87 (m, 6H), 7.81 (s, 2H), 7.57-7.51 (m, 6H), 6.08 (s, 4H), 5.85 (s, 2H), 3.71 (m, 2H), 
3.34 (m, 2H), 3.29 (m, 2H), 3.20 (m, 2H), 3.09 (s, 3H), 2.32 (s, 6H). 13C{1H} NMR (125 MHz, 
DMSO-d6) δ 148.1, 137.1, 132.6, 132.5, 131.8, 129.7, 128.6, 127.7, 127.6, 126.6, 126.1, 124.9, 
113.4, 70.9, 69.4, 59.8, 57.9, 48.9, 20.0. MS (ESI+) calcd for C37H29N2O3+ [M-Br]+ of m/z = 
559.3, found [M-Br]+ of m/z = 559.2. 
2-((2-(2-methoxyethoxy)ethoxy)methyl)-5,6-dimethyl-1,3-bis(quinolin-2-ylmethyl)-
benzimidazolium chloride salt (12). 2-((2-(2-methoxyethoxy)ethoxy)methyl)-5,6-
dimethylbenzimidazole (10) (0.200 g, 0.718 mmol) was dissolved in acetonitrile (2 mL), sodium 
carbonate (0.0774 g, 0.718 mmol) was added, and the mixture was refluxed for 30 min. 2-
(Chloromethyl)quinoline (0.143 g, 0.790 mmol) was added to the flask and the mixture was 
refluxed overnight. The reaction mixture was filtered hot to remove a white solid, presumed to be 
potassium bromide. 2-(Chloromethyl)quinoline (0.143 g, 0.790 mmol) was added to the filtrate, 
which was refluxed overnight. The resulting precipitate was filtered hot and the solid was 
transferred to a round bottom flask. The brown residue was washed at room temperature in 
acetonitrile, the solvent was decanted away and the solid was washed with diethyl ether at room 
temperature to yield an off-white solid. The white solid was purified by column chromatography 
using a mobile phase of methanol/chloroform (5:95) to yield an off-white solid 12 (0.02 g, XX
%). Mp: 200–203 °C. Anal. Calculated for C35H37ClN4O3: HR-MS (ESI+) calculated for 
C35H37N4O3+ [M-Cl]+  of m/z = 561.2866, found [M-Cl]+ of m/z = 561.2791. 1H NMR (500 
MHz, DMSO- d6) 8.50 (d, 2H), 8.12 (dd, 2H), 8.02 (d, 2H), 7.76 (d, 2H), 7.68 (m, 4H), 7.66-7.60 
(m, 4H), 6.39 (s, 4H), 5.47 (s, 2H), 3.65 (tt, 2H), 3.22 (tt, 4H), 3.19 (tt, 2H), 3.09 (s, 3H), 2.33 (s, 
6H). 13C {1H} NMR (100 MHz, DMSO-d6) 153.8, 149.9, 146.7, 137.5, 136.8, 130.0, 129.9, 
128.4, 127.9, 127.0, 126.9, 119.7, 113.1, 70.9, 70.2, 69.3, 69.2, 61.1, 57.9, 49.9, 19.9. 
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Appendix 1:
Safety Precautions
Basic Precautions 
 When working in a chemistry lab, safety is a key issue. Every chemist should be aware of 
basic lab safety, as well as any special safety considerations for any specific chemicals being 
used in an experiment. Basic safety measures to be aware of include, but are not limited to: 
wearing gloves, wearing protective eye gear, not wearing any loose clothing or accessories in the 
lab, no food or drink near the chemicals or in the lab, and always working reactions inside a 
ventilated hood. All of these safety measures were observed during the completion of this 
project. 
 Another safety consideration when working in the lab is being aware of any and all wash 
stations, including eye wash stations, safety showers, and sinks. Also, it is important to know 
how to use these wash stations properly. If any chemical splashes or touches the skin when 
working in the lab, one should immediately wash the affected area for at least 15 minutes, 
regardless of the toxicity of the chemical spilled.  
 Broken glassware or glass pipettes must be disposed of in the designated waste 
containers. This prevents possible injury to anyone unaware of broken glass or pipettes disposed 
of in the regular trash. Also, other disposable lab equipment, such as syringe and needle units, 
must be disposed of properly in a designated sharps container. In this project, 5 mL syringes 
were used to transfer the 2-(2-[2-methoxy]ethoxy)ethoxy acetic acid into the reaction flask. 
Following use, the soiled syringes and needle caps were disposed of in a designated sharps 
container. 
 This experiment also involved work with column chromatography, which has its own 
specific safety precautions. The stationary phase of the columns consisted of silica gel, which 
may induce silicosis if inhaled. To prevent silicosis, a respirator or breathing mask was worn in 
addition to standard protective equipment. 
Chemical-Specific Precautions 
 One of the main reactants for compounds 4-9 was o-phenylenediamine (Figure S1). The 
compound was stored under room temperature conditions on a high shelf. The compound was 
labelled as a suspected carcinogen, or cancer-inducing substance, so, in addition to basic safety 
precautions, a long-sleeved lab coat was worn to minimize the chance of the o-phenylenediamine 
coming into contact with skin.  
 
Figure S1. Structure of o-phenylenediamine 
 The other main reactant for compounds 5-9 was γ-butyroactone (Figure S2). The 
compound was stored under room temperature conditions on a high shelf. It is a viscous liquid at 
room temperature and was added to the solution via needle syringe. The only additional safety 
precaution taken for this compound was the proper disposal of the needle syringe in the 
designated sharps container. 
NH2 NH2
 Figure S2. Structure of γ-butyroactone 
 The two main reactants for compounds 10-12 were 4,5-dimethyl-o-phenylenediamine and 
2-(2-[2-methoxy]ethoxy)ethoxy acetic acid (Figure S3). The 4,5-dimethyl-o-phenylenediamine 
was stored under room temperature conditions on a high shelf. Similar to the o-
phenylenediamine, 4,5-dimethyl-o-phenylenediamine is labelled as a suspected carcinogen and a 
long-sleeved lab coat was worn as an additional precaution to reduce chance of skin contact.  
 The 2-(2-[2-methoxy]ethoxy)ethoxy acetic acid was stored between 1°C-8°C in an 
Isotemp Fisher Scientific explosion-proof refrigerator to prevent degradation. The compound is a 
viscous liquid and was added to the reaction via a needle syringe, which was disposed of 
properly in the designated sharps container. 
 
Figure S3. Structures of 4,5-dimethyl-o-phenylenediamine (left) and 2-(2-[2-
methoxy]ethoxy)ethoxy acetic acid (right) 
 Other commonly used compounds in these syntheses were 2-(bromomethyl)naphthalene, 
2-(chloromethyl) hydrochloride, and potassium hydroxide, none of which required special safety 
O
O
NH2 NH2
OOOHO
O
measures. The 2-(bromomethyl)napthalene (Figure S4) was stored between 1°C-8°C in an 
Isotemp Fisher Scientific explosion-proof refrigerator to prevent degradation. Standard safety 
measures were observed when handling the compound. 
 The 2-(chloromethyl) hydrochloride (Figure S5) was stored under room temperature 
conditions on a high shelf. Standard safety measures were observed when handling the 
compound.  
 The potassium hydroxide was stored under room temperature conditions on a high shelf. 
Standard safety measures were observed when handling the compound. 
 
Figure S4. Structure of 2-(bromomethyl)naphthalene 
 
Figure S5. Structure of 2-(chloromethyl)quinoline hydrochloride 
 Thionyl chloride was one other chemical used in this experiment (Figure S6). This 
compound was used in the synthesis of the 6-(methoxy)-2-(bromomethyl)naphthalene substituent 
used in compound 9. The thionyl chloride was stored under room temperature conditions on a 
high shelf. This chemical was only used in a hood while wearing a respirator or mask, in addition 
to basic safety precautions, and under the supervision of a graduate student. Thionyl chloride is 
Br
N Cl
HCl
an extremely toxic substance and can react violently with water. This chemical was and should 
be used with extreme caution. 
 
Figure S6. Structure of thionyl chloride 
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Appendix 2:
Table of Compounds
Table S1. Compound numbers, compound names, and compound structures
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Compound # Compound name Compound Structure
1 4,5-dichloro-1,3-bis(naphthalen-2-ylmethyl)imidazolium 
bromide; IC23
2 1,3-bis(naphthalen-2-ylmethyl)benzimidazolium bromide;             
IC23Benz
3 1,3-bis(naphthalen-2-ylmethyl)imidazolium bromide;             
IC23H
4 2-(3-hydroxypropyl)benzamidizole
5 2-(3-hydroxypropyl)-N,N’-bis(naphthalen-2-
ylmethyl)benzimidazolium bromide
6 2-(3-hydroxypropyl)-N-(naphthalen-2-ylmethyl)-N’-
(quinolin-2-ylmethyl)benzimidazolium chloride
7 2-(3-hydroxypropyl)-N-(naphthalen-2-ylmethyl)-N’-
(quinolin-2-ylmethyl)benzimidazolium bromide
8 2-(3-hydroxypropyl)-N,N’-bis(quinolin-2-
ylmethyl)benzimidazolium chloride
9 2-(3-hydroxypropyl)-N,N’-bis(6-methoxy-naphthalen-2-
ylmethyl)benzimidazolium chloride
10 2-((2-(2-methoxyethoxy)ethoxy)methyl)-5,6-dimethyl-
benzimidazole
11 2-((2-(2-methoxyethoxy)ethoxy)methyl)-5,6-dimethyl-N,N’-
bis(naphthalen-2-ylmethyl)benzimidazolium bromide
12 2-((2-(2-methoxyethoxy)ethoxy)methyl)-5,6-dimethyl-N,N’-
bis(quinolin-2-ylmethyl)benzimidazolium chloride
